Latest Biochip Stories

LEXINGTON, Mass. and HEIDELBERG, Germany, July 13 /PRNewswire/ -- febit holding gmbh announced today the launch of the first human cancer biochip for HybSelect, febit's highly automated technology for sequence capture, enabling targeted Next-Generation Sequencing (NGS). The new catalog cancer biochip features 115 important genes which are reported to be associated with common types of cancer by the Wellcome Trust Sanger Institute. "Molecular signatures defined by large-scale gene expression...

febit Technology Enables the Conversion of New Sequence Data into Biochips for Gene Expression Profiling and Sequence Capture for Next-Generation Sequencing Within Days LEXINGTON, Mass. and HEIDELBERG, Germany, June 29 /PRNewswire/ -- febit holding gmbh announced today the launch of the first biochip on the market covering the newly published whole mouse genome. The biochip from febit enables up-to-date profiling and enrichment of genes and SNPs of interest using Gene Expression Profiling,...

Several thousand test fields are tightly packed together on the tiny surface of a biochip. They permit the rapid analysis of substances, e.g. for diagnosing allergens in the blood. These biochips are already in widespread use for DNA testing. When it comes to proteins, such chips are difficult to produce. This is because the proteins have a defined three-dimensional structure by which they can interact specifically with other molecules and control biological processes. If they bind to a...

Patent Covers High-throughput, Anchorage-independent Assay for Screening Compounds for Inhibition of Cancer Cell Growth. PITTSBURGH, May 28 /PRNewswire/ -- Falcon Genomics, Inc. announced today that it has received U.S. Patent # 7,537,913 with claims covering the Company's Cancer BioChip System (CBCS) for the identification and validation of potential cancer targets in a high-throughput in vitro setting with great clinical translational potential. The patent claims are supported by...

Paul Keim brings deep knowledge in the field of medical microbiology, biodefense and pathogens to febit, the leader in microfluidic microarray DNA analysis technologies LEXINGTON, Mass. and HEIDELBERG, Germany, April 14 /PRNewswire/ -- febit today announced the recruitment of Paul Keim, Ph.D., for its Scientific Advisory Board. Dr. Keim is Senior Investigator and Director of the Pathogen Genomics Division at TGen (The Translational Genomics Research Institute) in Phoenix, Ariz., and...

HybSelect(TM) first to provide high coverage and megabase capacity for the next generation sequencing community LEXINGTON, Mass. and HEIDELBERG, Germany, March 16 /PRNewswire/ -- febit today announced the official launch of its new sequence capture technology HybSelect. In several biomedical studies of early access customers over the past months, HybSelect demonstrated superb enrichment factors and deep sequencing coverage for a broad range of human genes and genomic regions. As the first...

PARIS, March 16 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) today reported the publication in Lancet Oncology of a study conducted by Institut Gustave Roussy, which describes the identification of a deregulated cell function in breast cancer through the analysis of alternative RNA splicing [1]. Study data demonstrate that exons are differently expressed in malignant and benign lesions, and alternative transcripts determine the molecular characteristics of breast...

Simon Chin, founder, chairman, & CEO of Iris BioTechnologies (OTCBB: IRSB), a theranostics company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions, gave his acceptance speech for Frost & Sullivan's 2008 North American Technology Innovation Award in the field of Pharmacogenomics at the Growth Excellence Awards Banquet. The event was held Monday, September 15th at the Park 55 Hotel in San Francisco, CA. This award has...

President & Chairman Simon Chin of Iris BioTechnologies (OTCBB: IRSB), the Santa Clara, California-based theranostics company, that is focused on developing and commercializing the Nano-Biochip(TM), a gene expression system that identifies the most effective, reliable, and personalized treatment option for patients, was included in the "PharmaVOICE 100," an annual list of individuals who are having a remarkable influence on the life sciences industry. Mr. Chin's nomination and ultimate...

A group of Japanese researchers claim to have created artificial DNA. This breakthrough could greatly impact the realm of nano-scale computing, leading to the ultimate 'green' computer and endless possibilities for new biotechnology applications. In these early stages, when hopes are particularly high, it may be beneficial for companies to begin investing in research which emphasizes this medium. A team of researchers at the University of Toyama in Japan, led by Masahiko Inouye, claim to have...